Related references
Note: Only part of the references are listed.Varicella-zoster virus meningoencephalitis in a patient treated with ruxolitinib
Ophir Eyal et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib
Chih-Cheng Chen et al.
ANNALS OF HEMATOLOGY (2016)
Epstein-Barr virus gastric ulcer associated with ruxolitinib
Yoshiharu Kusano et al.
ANNALS OF HEMATOLOGY (2016)
Klebsiella pneumoniae primary liver abscess associated with ruxolitinib
Yoshiharu Kusano et al.
ANNALS OF HEMATOLOGY (2016)
Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib
Benoit Branco et al.
ANNALS OF HEMATOLOGY (2016)
Elevation of the Hepatitis B Virus DNA during the Treatment of Polycythemia Vera with the JAK Kinase Inhibitor Ruxolitinib
Keita Kirito et al.
INTERNAL MEDICINE (2016)
Case of disseminated molluscum contagiosum caused by ruxolitinib, a Janus kinase 1 and 2 inhibitor
Manao Kinoshita et al.
JOURNAL OF DERMATOLOGY (2016)
Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib
Joanna von Hofsten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
JAK1/2 inhibition impairs T cell function invitro and in patients with myeloproliferative neoplasms
Sowmya Parampalli Yajnanarayana et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms
Kathrin Schoenberg et al.
CANCER RESEARCH (2015)
A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Naveen Pemmaraju et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
Alessandro M. Vannucchi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immunological Consequences of JAK Inhibition: Friend or Foe?
Donal P. McLornan et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge
Francesca Palandri et al.
ANNALS OF HEMATOLOGY (2015)
Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis
Yen-Hao Chen et al.
LEUKEMIA & LYMPHOMA (2015)
Disseminated Infections with Talaromyces marneffei in Non-AIDS Patients Given Monoclonal Antibodies against CD20 and Kinase Inhibitors
Jasper F. W. Chan et al.
EMERGING INFECTIOUS DISEASES (2015)
Hepatitis B virus reactivation associated with ruxolitinib
Chien-Heng Shen et al.
ANNALS OF HEMATOLOGY (2014)
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts
Francesco Passamonti et al.
BLOOD (2014)
Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment
Lana X. Tong et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
G. Caocci et al.
LEUKEMIA (2014)
Disseminated tuberculosis associated with ruxolitinib
R. K. Hopman et al.
LEUKEMIA (2014)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
Annkristin Heine et al.
BLOOD (2013)
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
Annkristin Heine et al.
BLOOD (2013)
An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
Nicholas G. Wysham et al.
CHEST (2013)
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Srdan Verstovsek et al.
HAEMATOLOGICA (2013)
Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
Ruben A. Mesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Ruxolitinib can mask symptoms and signs of necrotizing fasciitis
G. W. D. Landman et al.
JOURNAL OF INFECTION (2013)
Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
Rowan Wathes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib
Roger A. Goldberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Share Paper
